Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
The Conversation logo

We are entering a new era as a species. For the first time, we are not only able to read our genetic code but also edit it. This will revolutionise our ability to treat disease and it will improve the lives of millions if not billions of people. But it means that, if we want to, we can now edit human embryos to “improve” the characteristics of our children. We will be able to create designer babies and these changes will be passed on to their descendants, which will change the human species forever.

It is worth thinking about the scale of what we can now do. The human genome is made up of 3 billion characters, which is about ten times the size of Encyclopaedia Britannica. This contains all the information needed to make a human, and it determines nearly all our characteristics as individuals (not only height, athletic performance and IQ but also our personality and even political views). We completed the first sequence of the human genome around 20 years ago at a cost of US $2.7 billion. We can now sequence a genome for less than the cost of an MRI scan.

Read the full article on The Conversation website, written by James Davies, Postdoctoral Researcher, MRC Weatherall Institute of Molecular Medicine (Radcliffe Department of Medicine).

Oxford is a subscribing member of The ConversationFind out how you can write for The Conversation.

Similar stories

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Parental mental health worsens under new national COVID-19 restrictions

Coronavirus COVID-19 General Research

Parental stress, depression and anxiety have again increased since new national restrictions have been introduced, according to the latest report from the Oxford University-led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study, based on data from over 6000 UK parents.

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Awards and Appointments General Innovation

A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.